Treatment outcomes for Hodgkin lymphoma: First report from the Brazilian Prospective Registry
Abstract
Data about Hodgkin lymphoma (HL) in developing countries are scarce and suggest the existence of substantial disparities in healthcare and outcomes in large areas of the world. In 2009, a prospective registry of HL was implemented in Brazil. Web‐based data were contributed by 20 institutions across the country participating in the Brazilian Prospective Hodgkin's Lymphoma Registry. The aim of this study was to present the clinical features and outcomes of newly diagnosed patients with HL aged 13 to 90 years. Multivariate Cox regression models were used to estimate progression‐free (PFS) and overall survival (O...
Source: Hematological Oncology - June 1, 2017 Category: Hematology Authors: Irene Biasoli, Nelson Castro, Marcia Delamain, Talita Silveira, James Farley, Belinda Pinto Sim ões, Cristiana Solza, Monica Praxedes, Otávio Baiocchi, Rafael Gaiolla, Fernanda Franceschi, Caroline Bonamin Sola, Carla Boquimpani, Nelma Clementino, Guilh Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Response and survival benefit with chemoimmunotherapy in Epstein ‐Barr virus‐positive diffuse large B‐cell lymphoma
Abstract
Epstein‐Barr virus (EBV)‐positive diffuse large B‐cell lymphoma (DLBCL) is a haematologic malignancy with poor prognosis when treated with chemotherapy. We evaluated response and survival benefits of chemoimmunotherapy in EBV‐positive DLBCL patients. A total of 117 DLBCL patients were included in our retrospective analysis; 33 were EBV‐positive (17 treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R‐CHOP] and 16 with CHOP), and 84 were EBV‐negative (all treated with R‐CHOP). The outcomes of interest were complete response (CR) and overall survival (OS) in EBV‐pos...
Source: Hematological Oncology - June 1, 2017 Category: Hematology Authors: Brady E. Beltran, Pilar Qui ñones, Domingo Morales, Jose M. Malaga, Julio C. Chavez, Eduardo M. Sotomayor, Jorge J. Castillo Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Persistently low lymphocyte counts after FCR therapy for chronic lymphocytic leukemia are associated with longer overall survival
In conclusion, lower ALC levels in the first few months following frontline FCR therapy were associated with longer OS and EFS. Possible explanations may be that lower ALCs reflect deeper clonal suppression or protracted Treg depletion. Absolute lymphocyte count levels may be a cheap and widely available prognostic marker, though the added value for clinical practice is the minimal residual disease era needs to be explored. (Source: Hematological Oncology)
Source: Hematological Oncology - June 1, 2017 Category: Hematology Authors: Erel Joffe, Ariela Arad N., Osnat Bairey, Riva Fineman, Rosa Ruchlemer, Naomi Rahimi ‐Levene, Lev Shvidel, Uri Greenbaum, Ariel Aviv, Tamar Tadmor, Andrei Braester, Neta Goldschmidt, Aaron Polliack, Yair Herishanu Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Pharmacokinetic study of bortezomib administered intravenously in Taiwanese patients with multiple myeloma
Abstract
This phase 4, single‐arm, non‐randomized, open‐label, post approval commitment study evaluated the pharmacokinetics and safety of bortezomib in Taiwanese patients with multiple myeloma. Patients (≥20 years) with measurable secretory multiple myeloma (serum monoclonal IgG ≥10, IgA/IgE ≥5, IgD ≥0.5 g/L, IgM present [regardless of level], and urine M protein of ≥200 mg/24 h) received intravenous bortezomib 1.3 mg/m2, twice weekly for 2 weeks, followed by a 10‐day resting phase (days 12 to 21). Pharmacokinetics and safety were assessed at pre‐specified time points. All enrolled patients (n...
Source: Hematological Oncology - June 1, 2017 Category: Hematology Authors: Shang ‐Yi Huang, Cheng‐Shyong Chang, Ta‐Chih Liu, Po‐Nan Wang, Su‐Peng Yeh, Ching‐Liang Ho, Ming‐Chung Kuo, Hsuan‐Yu Lin, Jan Jong, Jia‐Yi Chen, Ya‐Wen Yang Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Outcome of patients older than 80 years with diffuse large B‐cell lymphoma (DLBCL) treated with “standard” immunochemotherapy: A large retrospective study from 4 institutions
Abstract
Little information is available on the very elderly patients with diffuse large B‐cell lymphoma (DLBCL). We performed a retrospective analysis of 281 patients >80 years old with newly diagnosed DLBCL treated in 4 referral institutions in Switzerland and Northern Italy. Primary end points were overall survival, progression‐free survival, and cause‐specific survival. Systemic chemotherapy was given to 239 patients, and 119 of them received rituximab in their initial treatment. At a median follow‐up of 5.5 years, 5‐year progression‐free survival was 26% (95% confidence interval [CI], 20‐32%), 5‐y...
Source: Hematological Oncology - June 1, 2017 Category: Hematology Authors: Stefania Gobba, Alden A. Moccia, Wiebke Gulden ‐Sala, Annarita Conconi, Stefan Diem, Luciano Cascione, Gloria Iacoboni, Gloria Margiotta‐Casaluci, Kathrin Aprile von Hohenstaufen, Anastasios Stathis, Felicitas Hitz, Graziella Pinotti, Gianluca Gaidano Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Complete remission with romidepsin in a patient with T ‐cell acute lymphoblastic leukemia refractory to induction hyper‐CVAD
Hematological Oncology,Volume 36, Issue 1, Page 340-343, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - May 30, 2017 Category: Hematology Source Type: research
---
Hematological Oncology,Volume 36, Issue 1, Page 340-343, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - May 30, 2017 Category: Hematology Source Type: research
Emergence of MPLW515 mutation in a patient with CALR deletion: Evidence of secondary acquisition of MPL mutation in the CALR clone
Hematological Oncology,Volume 36, Issue 1, Page 336-339, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - May 29, 2017 Category: Hematology Source Type: research
---
Hematological Oncology,Volume 36, Issue 1, Page 336-339, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - May 29, 2017 Category: Hematology Source Type: research
Confocal endomicroscopy in diagnosis of intestinal chronic graft ‐versus‐host disease
Hematological Oncology,Volume 36, Issue 1, Page 291-298, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - May 25, 2017 Category: Hematology Source Type: research
---
Hematological Oncology,Volume 36, Issue 1, Page 291-298, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - May 25, 2017 Category: Hematology Source Type: research
Are we ready to take full advantage of patient ‐derived tumor xenograft models?
Hematological Oncology,Volume 36, Issue 1, Page 24-27, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - May 23, 2017 Category: Hematology Source Type: research
---
Hematological Oncology,Volume 36, Issue 1, Page 24-27, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - May 23, 2017 Category: Hematology Source Type: research
Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B ‐cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi
Hematological Oncology,Volume 36, Issue 1, Page 68-75, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - May 19, 2017 Category: Hematology Source Type: research
---
Hematological Oncology,Volume 36, Issue 1, Page 68-75, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - May 19, 2017 Category: Hematology Source Type: research
